Advertisement
You are not currently logged in.
Login
or
Register
Get Email Updates
Patients » Visit TheBody.com
0
Email
Emtricitabine (FTC, Emtriva)
The Basics
|
Research
See also:
Drug Interactions
|
Adverse Events of HIV/HAART
Overview
Prescribing Information for Emtricitabine (FTC, Emtriva) (PDF)
(November 2011)
From Gilead Sciences, Inc.
Labeling Changes for Emtriva
(September 28, 2005)
Specific modifications since the label was last updated are highlighted.
From
U.S. Food and Drug Administration
Approval of Emtriva for Treating HIV
(July 2, 2003)
From
U.S. Food and Drug Administration
FTC Has Been Approved: What Now?
(July 2003)
An analysis of what we know so far -- and what we have yet to learn.
In
TAGline
, from
Treatment Action Group
Separated at Birth: 3TC and FTC
(July 2003)
A quick comparison of molecular structures.
In
TAGline
, from
Treatment Action Group
Research & News
Switching to Rilpivirine/Tenofovir/FTC Fixed-Dose Combination From Boosted-PI Regimen: SPIRIT Study Draws the Line at 24 Weeks
(July/August 2012)
To read PDF,
click here
.
In
HIV Treatment Bulletin
, from
HIV i-Base
Prospective Randomized Trial of Emtricitabine Versus Lamivudine Short-Term Monotherapy in Human Immunodeficiency Virus-Infected Patients
In
Journal of Infectious Diseases
Gilead and Tibotec Agree on New Single-Tablet Regimen
(November 23, 2011)
In
Positively Aware
, from
Test Positive Aware Network
Gilead and J&J Expand HIV Cocktail Partnership
(November 16, 2011)
In
CDC HIV/Hepatitis/STD/TB Prevention News Update
, from
U.S. Centers for Disease Control and Prevention
Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike
(April 4, 2011)
In
Bloomberg Businessweek
Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways
(February 6, 2006)
In
The 13th Conference on Retroviruses and Opportunistic Infections
Emtriva: New Pediatric Formulation and Labeling Changes
(September 28, 2005)
From
U.S. Food and Drug Administration
Gilead, Royalty Pharma to Pay Emory University $525 Million for Rights to Emtricitabine
(July 19, 2005)
In
Kaiser Daily HIV/AIDS Report
, from
Henry J. Kaiser Family Foundation
No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine
(February 25, 2005)
In
The 12th Conference on Retroviruses and Opportunistic Infections
, from TheBodyPRO.com
Two New Fixed-Dose Combinations Approved
(August 2, 2004)
From
U.S. Food and Drug Administration
VIEW ALL ARTICLES
Advertisement
Advertisement
MOST VIEWED ARTICLES
HIV Management Today
: Mental Health & HIV, the Uncharted Territory
CROI 2013: Research on Aging and HIV (Video)
Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
HIV Opportunistic Infection Guidelines Updated
More Most Viewed Articles